Poster Presentation

NAV-003, Bispecific Targeting Mesothelin With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors

 

Poster Presentation

BRITE Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression

 

Publication

CA125 suppresses ADCC via direct antibody binding and suppressed Fc-γ receptor engagement

 

Publication

Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding

 

Poster Presentation

Development of NAV-005, a humoral immuno-suppressor antagonist for the treatment of CA125-expressing cancers